Document Detail

In vitro interaction of high-LET heavy-ion irradiation and chemotherapeutic agents in two cell lines with different radiosensitivities and different p53 status.
MedLine Citation:
PMID:  20651340     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: To investigate the differences between two rat yolk sac tumor cell lines with different radiosensitivities and p53 status in sensitivity to high-LET heavy-ion beam and in sensitizing effect of etoposide or cisplatin in combination with heavy-ion beam. MATERIALS AND METHODS: NMT-1 (wild-type p53 cell) is a parent radiosensitive cell line and NMT-1R (mutant-type p53 cell) is a variant radioresistant cell line. Heavy ion (carbon ion) was accelerated to 290 MeV per nucleon by a heavy-ion medical accelerator in Chiba at National Institute of Radiological Sciences. The effects of carbon ion irradiation and carbon ion irradiation plus chemotherapeutic agents were assessed by clonogenic assay. RESULTS: There was no significant difference between NMT-1 cells and NMT-1R cells in sensitivity to high-LET heavy-ion irradiation. The RBE of carbon beam was larger in mutant-type p53 cells than in wild-type p53 cells. Etoposide showed a supra-additive effect in combination with carbon beam irradiation in NMT-1R cells. Etoposide potentiation in NMT-1R cells was manifested by the decrease in the slope of the radiation dose-response curve. On the other hand, cisplatin had no enhancement of radiosensitivity in either cell lines. CONCLUSION: Our findings suggested that high-LET radiotherapy is expected to be effective for patients carrying radioresistant tumors and mutated p53 tumor cells. Etoposide might be effective for radioresistant tumors in combination with heavy-ion beam irradiation.
Takeo Takahashi; Takeshi Fukawa; Ryoichi Hirayama; Yukari Yoshida; Atsushi Musha; Yoshiya Furusawa; Koichi Ando; Takashi Nakano
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Anticancer research     Volume:  30     ISSN:  1791-7530     ISO Abbreviation:  Anticancer Res.     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-07-23     Completed Date:  2010-08-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  1961-7     Citation Subset:  IM    
Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / pharmacology*
Cell Line, Tumor
Combined Modality Therapy
Dose-Response Relationship, Radiation
Etoposide / pharmacology*
Genes, p53*
Heavy Ions / therapeutic use*
Linear Energy Transfer*
Neoplasms / genetics,  therapy*
Radiation Tolerance
Reg. No./Substance:
0/Antineoplastic Agents; 33419-42-0/Etoposide; 7440-44-0/Carbon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Guggulsterone Suppresses Bile Acid-induced and Constitutive Caudal-related Homeobox 2 Expression in ...
Next Document:  KRAS and BRAF mutation analysis from liquid-based cytology brushings of colorectal carcinoma in comp...